Telatinib - Bayer/Eddingpharm

Drug Profile

Telatinib - Bayer/Eddingpharm

Alternative Names: BAY-57-9352; Telatinib mesylate

Latest Information Update: 07 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer ACT Biotech; Eddingpharm
  • Class Antineoplastics; Furans; Pyridazines; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer
  • Phase I Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 25 Jul 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT03175497)
  • 13 Jun 2017 Eddingpharm Oncology plans a phase I trial to evaluate the safety and pharmacokinetics of telatinib in patients with advanced Solid tumours, in China (NCT03175497)
  • 13 Mar 2017 OncBioMune Pharmaceuticals announces term sheet with EOC Pharma for development of telatinib in Mexico, Central America and Latin America for Gastric cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top